Consulting agreement for advisory services on chromatin remodeling products, with a share grant and consulting fee.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Adrian Gottschalk
Also a director
Chief Executive Officer and Director (Class II)
|
50 | Not stated | Not stated | $2,361,027 | |
|
Ryan Maynard
Chief Financial Officer
|
56 |
Since 2026
this year
|
Not stated | Not reported | |
|
Steven Bellon
Chief Scientific Officer
|
61 |
Since 2022
4 years
|
Not stated | $1,199,455 | |
|
Carlos Costa
Chief People Officer
|
53 |
Since 2022
4 years
|
2018 | Not reported | |
|
Michael LaCascia
Chief Legal Officer
|
61 |
Since 2020
6 years
|
Not stated | Not reported | |
|
Alfonso Quintás-Cardama
Chief Medical Officer
|
55 |
Since 2023
3 years
|
Not stated | $1,133,965 | |
|
Anna Rivkin
Chief Business Officer
|
52 |
Since 2024
2 years
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Consulting agreement for advisory services on chromatin remodeling products, with a share grant and consulting fee.
Payments to Dr. Kadoch under the consulting agreement.
Strategic collaboration under the Lilly Collaboration Agreement, with a stock purchase of 4,000,000 shares at $20.00 per share and shared program costs.
Payments by the Company to Lilly for 2025 under the collaboration.
Purchase of common stock and pre-funded warrants in the January 2026 equity offering.
Purchase of pre-funded warrants in the January 2026 equity offering.
Purchase of common stock in the January 2026 equity offering.
Purchase of common stock in the January 2026 equity offering.
Loading...